Hypertension is simultaneously a cause and a consequence of virtually every major form of cardiovascular disease. In patients who have already developed coronary artery disease (CAD), heart failure, atrial fibrillation (AF), or who have experienced a myocardial infarction (MI), the pharmacological management of hypertension is no longer simply about lowering blood pressure (BP): it is about selecting agents whose mechanisms of action address both the hypertension and the underlying cardiovascular disease simultaneously.1,2 These are the patients in whom the concept of compelling indications is most powerfully expressed, where a specific drug class produces outcome benefits that substantially exceed what would be predicted from BP reduction alone. This final module synthesizes the evidence for antihypertensive pharmacotherapy across the major cardiovascular comorbidities: heart failure with reduced and preserved ejection fraction, post-MI, stable CAD, atrial fibrillation, aortic disease, and peripheral arterial disease (PAD). It concludes with an integrated summary of BP targets across cardiovascular comorbidities.
Hypertension is the leading attributable risk factor for heart failure in the United States, contributing to approximately 75% of heart failure cases through sustained pressure overload leading to left ventricular hypertrophy (LVH) and eventual systolic dysfunction, acceleration of atherosclerosis and MI-related cardiomyopathy, direct angiotensin II-mediated myocardial fibrosis and remodeling, and promotion of AF, the most common cause of tachycardia-induced cardiomyopathy.1,3 Conversely, established heart failure with reduced ejection fraction (HFrEF) perpetuates hypertension through neurohormonal activation: renin-angiotensin-aldosterone system (RAAS) upregulation, sympathetic nervous system (SNS) activation, and vasopressin release all increase peripheral resistance and promote sodium retention.
The current four-pillar guideline-directed medical therapy (GDMT) for HFrEF consists of the following.3,4 Pillar 1: Angiotensin pathway inhibition. Sacubitril/valsartan is preferred; the PARADIGM-HF trial demonstrated it is superior to enalapril in reducing cardiovascular mortality and HF hospitalization by 20% in patients with left ventricular ejection fraction (LVEF) ≤40%. An ACEi or ARB is used when sacubitril/valsartan is not tolerated or affordable. Sacubitril/valsartan must never be combined with an ACEi; a 36-hour washout from any ACEi is required before initiation to prevent angioedema. Pillar 2: Beta-blocker. Three beta-blockers have proven mortality benefit: carvedilol (COPERNICUS: 35% mortality reduction in severe HFrEF5), metoprolol succinate (MERIT-HF: 34% mortality reduction6), and bisoprolol (CIBIS-II: 34% mortality reduction7). Beta-blockers must be started at the lowest possible dose when HF is stable and uptitrated slowly; they must not be initiated during acute decompensation.
Pillar 3: Mineralocorticoid receptor antagonist (MRA). Spironolactone (RALES trial: 30% mortality reduction in severe HFrEF8) or eplerenone (EMPHASIS-HF: 37% reduction in cardiovascular mortality and HF hospitalization in mild HFrEF9) is indicated in all patients with HFrEF (LVEF ≤35%) already on an ACEi, ARB, or sacubitril/valsartan and a beta-blocker. Potassium and creatinine must be monitored closely. MRAs are contraindicated when potassium is >5.0 mEq/L, creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women), or estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m². Pillar 4: sodium-glucose cotransporter 2 (SGLT2) inhibitor. Dapagliflozin (DAPA-HF trial: 26% reduction in composite of cardiovascular death, HF hospitalization, or urgent HF visit regardless of diabetes status10) and empagliflozin (EMPEROR-Reduced) are now Class I GDMT for HFrEF and provide a modest antihypertensive effect of 3–5 mmHg systolic BP reduction as an added benefit.
The target BP in HFrEF is <130/80 mmHg per ACC/AHA 2017 guidelines.1 In severe HFrEF (LVEF <25%, very low cardiac output [CO]), BP may already be low; antihypertensive dose adjustment or discontinuation may be necessary, and systolic BP <90 mmHg should be avoided as it impairs coronary and renal perfusion. A critical distinction governs CCB use in HFrEF: non-dihydropyridine (non-DHP) CCBs (verapamil, diltiazem) are absolutely contraindicated due to negative inotropy that worsens systolic function and outcomes. Dihydropyridine (DHP) CCBs (amlodipine) are safe in HFrEF; the PRAISE and PRAISE-2 trials demonstrated amlodipine does not worsen HF outcomes, and amlodipine is the only CCB that can safely be added to HFrEF GDMT when additional BP control is needed.
Heart failure with preserved ejection fraction (HFpEF; LVEF ≥50% with symptoms and signs of heart failure) is predominantly driven by hypertension and its consequences.1,11 Pressure overload from hypertension causes concentric LVH and myocardial fibrosis, producing a stiff, non-compliant left ventricle. Diastolic dysfunction follows: impaired LV relaxation and increased filling pressures produce HF symptoms despite preserved systolic function. Left atrial enlargement and elevated pulmonary pressures develop in sequence. Hypertension is the most important modifiable risk factor for HFpEF; effective BP control is the most powerful intervention for its prevention and management, and the BP target is <130/80 mmHg.1
Unlike HFrEF, HFpEF lacks robust evidence for specific drug classes conferring mortality benefit. RAAS inhibitors (ACEi or ARB) are recommended for BP control and LVH regression despite negative primary endpoint results in the I-PRESERVE (irbesartan) and CHARM-Preserved (candesartan) trials, given their favorable effects on cardiac remodeling. MRAs: the TOPCAT trial (spironolactone) did not meet its primary endpoint but showed significant reduction in HF hospitalizations in subgroup analysis; spironolactone is widely used in HFpEF for its antifibrotic and diuretic effects. Finerenone showed benefit in the FINEARTS-HF trial (2024), the first major positive MRA trial in HFpEF, and is emerging as a preferred MRA in this setting.
SGLT2 inhibitors (EMPEROR-Preserved and DELIVER trials) significantly reduced composite cardiovascular death and HF hospitalization in HFpEF and are now Class IIa or Class I GDMT regardless of diabetes status. Loop and thiazide diuretics are essential for symptomatic volume management and quality of life in HFpEF without reducing mortality. DHP CCBs (amlodipine) are safe in HFpEF and useful for BP control and concurrent angina.
Following MI, antihypertensive therapy serves the dual purpose of BP control and prevention of adverse cardiac remodeling. The evidence-based post-MI drug regimen addresses both simultaneously.1,2,12 ACEi or ARB (mandatory if LVEF ≤40% or anterior MI) reduce infarct expansion and ventricular remodeling through angiotensin II suppression and prevent progression to heart failure. Multiple landmark trials (GISSI-3, ISIS-4, SAVE, TRACE, AIRE) confirmed mortality reduction with ACEi post-MI. ACEi are preferred; ARBs are acceptable in ACEi-intolerant patients, as the VALIANT trial demonstrated valsartan non-inferior to captopril. Beta-blockers reduce sympathetic activation following MI (ventricular arrhythmias, sudden death, and reinfarction). Carvedilol, metoprolol succinate, or bisoprolol are used when LVEF is reduced.
Eplerenone (EPHESUS trial): eplerenone initiated within 3–14 days post-MI in patients with LVEF ≤40% and either HF symptoms or diabetes reduced all-cause mortality by 15% and cardiovascular mortality and morbidity by 13%.13 It is indicated in post-MI patients with LVEF ≤40% and either symptomatic HF or diabetes, already on an ACEi and beta-blocker. Agents to avoid post-MI include non-DHP CCBs (verapamil, diltiazem), which are contraindicated if LVEF is reduced due to negative inotropy, and short-acting DHP CCBs (immediate-release nifedipine), which are contraindicated because reflex tachycardia increases myocardial oxygen demand. The BP target post-MI is <130/80 mmHg per ACC/AHA 2017 guidelines, with avoidance of DBP <65–70 mmHg to preserve coronary perfusion (the J-curve consideration).1
In patients with hypertension and established stable CAD, certain antihypertensives provide dual benefits: BP control and reduction of ischemic symptoms or events.1,2 Beta-blockers reduce myocardial oxygen demand through heart rate reduction and decreased contractility, are indicated for symptom control in angina, and reduce recurrent MI and sudden death in post-MI patients. Long-acting DHP CCBs (amlodipine, long-acting nifedipine) produce coronary arteriolar vasodilation that reduces anginal episodes. The CAMELOT trial demonstrated amlodipine reduced cardiovascular events and slowed atherosclerosis progression in CAD patients even with normal or mildly elevated BP, supporting its use as a first-line add-on when beta-blockers do not fully control angina.
ACEi or ARBs provide secondary prevention benefit: the HOPE trial (ramipril: 22% cardiovascular event reduction in high-risk patients including many with CAD) and EUROPA trial (perindopril: 20% cardiovascular event reduction in stable CAD) support their use in all patients with CAD and reduced LVEF, CKD, diabetes, or other compelling indications.
The J-curve is most clinically important in stable CAD: coronary perfusion occurs primarily during diastole, and reducing DBP below 65–70 mmHg in patients with significant coronary stenosis may reduce perfusion pressure distal to the stenosis. Practical guidance: monitor carefully for anginal symptoms at DBP <70 mmHg and avoid excessive diastolic lowering in patients with known significant coronary stenosis. Agents to avoid in stable CAD include short-acting DHP CCBs (reflex tachycardia; historically associated with increased MI risk) and the combination of non-DHP CCBs with beta-blockers (severe bradycardia, AV block, and additive negative inotropy).
Hypertension is the most common modifiable risk factor for AF. LVH, left atrial enlargement, interstitial fibrosis, RAAS activation, and angiotensin II-driven myocardial fibrosis collectively create the structural and electrical substrate for AF. Approximately 60–80% of patients with AF have hypertension as a comorbid condition.1,2 The choice of rate-controlling agent for AF should account for the concurrent antihypertensive need. Beta-blockers (metoprolol, bisoprolol, carvedilol) are first-line for rate control in AF in most patients, provide antihypertensive benefit through reduced cardiac output, and are preferred when concurrent HFrEF is present (carvedilol serves both as rate control and as GDMT). Non-DHP CCBs (diltiazem, verapamil) provide effective rate control through atrioventricular (AV) nodal slowing and antihypertensive benefit. They are absolutely contraindicated when HFrEF is present. They must not be combined with beta-blockers due to additive AV block and bradycardia risk. Both diltiazem and verapamil are potent cytochrome P450 3A4 (CYP3A4) inhibitors with significant drug-drug interaction potential; diltiazem is generally preferred for fewer drug interactions and less constipation than verapamil.
RAAS inhibitors reduce the risk of new-onset AF and of AF recurrence through prevention of atrial fibrosis (angiotensin II-mediated transforming growth factor beta pathway), reduction of left atrial size, and reduction of RAAS-mediated electrical remodeling. The LIFE trial demonstrated losartan significantly reduced new-onset AF compared with atenolol in hypertensive LVH patients as a pre-specified secondary endpoint, supporting RAAS inhibitors as upstream therapy for AF prevention in at-risk patients. For antithrombotic therapy, anticoagulation is determined by the CHA&sub2;DS&sub2;-VASc score; hypertension itself adds one point to this score. Well-controlled BP reduces the risk of intracranial hemorrhage on anticoagulation; a target of SBP <130 mmHg is recommended in patients with AF on anticoagulation.
In acute aortic dissection, the pharmacological priorities are simultaneous reduction of BP and heart rate to reduce the rate of aortic pressure rise (dP/dt). Beta-blockade is initiated first (IV esmolol or labetalol; target heart rate <60 bpm); vasodilators (sodium nitroprusside or nicardipine IV) are added only after heart rate is controlled, because vasodilation alone without heart rate control increases dP/dt through reflex tachycardia. Long-term post-dissection management targets SBP <120–130 mmHg using beta-blockers as the preferred agents, with ACEi or ARBs for additional aortic wall protection. In Marfan syndrome, losartan (ARB) has evidence for slowing aortic root dilation through inhibition of angiotensin II-mediated transforming growth factor beta signaling and is used in addition to beta-blockers. In non-Marfan thoracic and abdominal aortic aneurysm, rigorous BP control to SBP <130 mmHg reduces aneurysm expansion rate.
In PAD, ACEi or ARBs are the preferred antihypertensive agents; RAAS inhibition reduces cardiovascular events in patients with established peripheral vascular disease, as demonstrated by the HOPE trial which enrolled significant PAD populations.14 The traditional concern about beta-blockers worsening claudication with non-selective agents has not been confirmed in meta-analyses of cardioselective agents (bisoprolol, metoprolol); cardioselective beta-blockers are acceptable in PAD when a compelling cardiac indication exists. DHP CCBs are safe in PAD and their vasodilatory effect may modestly benefit claudication. The ankle-brachial index (ABI) should be routinely measured; an ABI <0.9 confirms PAD, and the higher arm BP should be used for antihypertensive monitoring in patients with significant PAD.
The following evidence-based BP targets apply across cardiovascular comorbidities per ACC/AHA 2017 and 2023 ESH guidelines.1,2 For HFrEF and HFpEF: <130/80 mmHg; in severe HFrEF avoid SBP <90 mmHg. For post-MI: <130/80 mmHg, with avoidance of DBP <65–70 mmHg (J-curve). For stable CAD: <130/80 mmHg, with avoidance of DBP <65–70 mmHg, particularly in patients with significant coronary stenosis. For AF: <130/80 mmHg, particularly to reduce intracranial hemorrhage risk on anticoagulation. For chronic aortic dissection: SBP <120–130 mmHg. For aortic aneurysm: SBP <130 mmHg. For PAD: <130/80 mmHg, using the arm with higher BP for monitoring.
The consistent theme across cardiovascular comorbidities is that the choice of antihypertensive agent matters as much as the BP target achieved. In HFrEF, GDMT agents simultaneously lower BP and reduce mortality through mechanisms beyond BP reduction alone. In post-MI patients, ACEi and beta-blockers prevent remodeling that would otherwise progress to HF. In AF, RAAS inhibitors reduce AF burden through upstream structural effects on the atrium. In aortic disease, beta-blockers protect through dP/dt reduction beyond simple BP lowering. This concept of mechanism-driven agent selection, rather than BP reduction as the sole goal, is the defining principle of hypertension pharmacotherapy in the presence of established cardiovascular disease.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127–e248.
doi:10.1016/j.jacc.2017.11.006Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071.
doi:10.1097/HJH.0000000000003480Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263–e421.
doi:10.1016/j.jacc.2021.12.012McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF). N Engl J Med. 2014;371(11):993–1004.
doi:10.1056/NEJMoa1409077Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med. 2001;344(22):1651–1658.
doi:10.1056/NEJM200105313442201MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007.
doi:10.1016/S0140-6736(99)04440-2CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.
doi:10.1016/S0140-6736(98)11181-9Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES). N Engl J Med. 1999;341(10):709–717.
doi:10.1056/NEJM199909023411001Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms (EMPHASIS-HF). N Engl J Med. 2011;364(1):11–21.
doi:10.1056/NEJMoa1009492McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995–2008.
doi:10.1056/NEJMoa1911303Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm. Eur Heart J. 2019;40(40):3297–3317.
doi:10.1093/eurheartj/ehz641O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2013;61(4):e78–e140.
doi:10.1016/j.jacc.2012.11.019Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction (EPHESUS). N Engl J Med. 2003;348(14):1309–1321.
doi:10.1056/NEJMoa030207Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (HOPE trial). N Engl J Med. 2000;342(3):145–153.
doi:10.1056/NEJM200001203420301Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet. 2002;359(9311):995–1003.
doi:10.1016/S0140-6736(02)08089-3